PUBLIC COMPANY
save$GPCRStructure Therapeutics Inc.
$GPCR17.36-4.46%South San Francisco, CA, USupdated 19h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
🐶 Hiring Signal
News
- Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancerResearchers found that only by targeting both the G protein-coupled receptor and its mutated internal molecular switch can uveal melanoma cell signaling be disrupted.fiercebiotech · 7d ago
- Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…endpoints · 2mo ago
- Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropStructure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…biospace · 2mo ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 2mo ago
- Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical modelsEfficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on…biospace · 2mo ago
- Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO→ Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. On April 1, 2027, the Japanese pharma will split the com…endpoints · 2mo ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 2mo ago
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 3mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3mo ago
- AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blowAstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.biospace · 3mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that